AU Patent

AU2017360346B2 — Transdermal delivery of large agents

Assigned to Eirion Therapeutics Inc · Expires 2023-11-23 · 2y expired

What this patent protects

Methods, compositions, and devices for enhancing transdermal delivery of large agents.

USPTO Abstract

Methods, compositions, and devices for enhancing transdermal delivery of large agents.

Drugs covered by this patent

aminolevulinic-acid-hydrochloride (AMINOLEVULINIC ACID HYDROCHLORIDE)

Patent Metadata

Patent number: AU2017360346B2
Jurisdiction: AU
Classification: —
Expires: 2023-11-23
Drug substance claim: No
Drug product claim: No
Assignee: Eirion Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.